Skip to main content

AS/Spondyloarthritis

      RT @doctorRBC: Drug retention of TNFi vs. secukinumab in AxSpA pts
      Abs#911
      ⭐️46% discontinued either treatment
      ⭐ï
      2 years 7 months ago
      Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
      RT @_Castillo_Pedro: Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
      🔹21
      2 years 7 months ago
      Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs https://t.co/Id658ocDVf #ACR21 Abst1777 @RheumNow
      RT @swethaann23: AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologi
      2 years 7 months ago
      AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently ⭐️🔽 clinic workload and better disease activity stratification Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
      Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annu
      2 years 7 months ago
      Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting. https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
      Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
      RT @RichardPAConway: Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA&gt;PsA&gt;AS&gt;PsO . HRs 1.1
      2 years 7 months ago
      Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
      RT @Janetbirdope: Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the
      2 years 7 months ago
      Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx